Abbott Laboratories (ABT) Liabilities and Shareholders Equity (2009 - 2026)

Abbott Laboratories has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $109.2 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 30.02% year-over-year to $109.2 billion; the TTM figure through Jun 2026 stood at $390.5 billion (up 21.58% YoY), while the FY2025 annual figure was $86.7 billion, up 6.51% from the prior year.
• Liabilities and Shareholders Equity came in at $109.2 billion for Q2 2026 at Abbott Laboratories, down from $110.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $110.4 billion in Q1 2026 to a low of $72.1 billion in Q3 2023.
• Average Liabilities and Shareholders Equity over 5 years is $80.3 billion, with a median of $74.3 billion recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity declined 1.8% in 2024 and soared 35.58% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $74.4 billion in 2022, then decreased by 1.64% to $73.2 billion in 2023, then rose by 11.2% to $81.4 billion in 2024, then climbed by 6.51% to $86.7 billion in 2025, then increased by 25.95% to $109.2 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $109.2 billion in Q2 2026, $110.4 billion in Q1 2026, and $86.7 billion in Q4 2025.